Literature DB >> 31930078

Clinical characteristics and genetic testing of an atypical familial von Hippel-Lindauzon renal cell carcinoma.

Jing Wang1, Feng Qi2,3, Ping Zhang2, Zicheng Xu2, Yuxiao Zheng2, Hongzhou Cai2, Bin Yu2, Ting Xu2, Xiao Li2, Qing Zou2.   

Abstract

BACKGROUND: A case of familial bilateral von Hippel-Lindauzon (VHL) renal cell carcinoma (RCC) was retrospectively reviewed and the etiological diagnosis was based on clinical characteristics and genetic testing.
METHODS: The clinical manifestations and imaging data were gained from the hospital information system (HIS). Peripheral blood samples were collected and genomic DNA and RNA were extracted. Additionally, mutations of VHL gene such as tiny insertion and deletion of base, point mutation and large deletion of gene were then detected and analyzed by DNA sequencing, real-time quantitative PCR and RT-PCR.
RESULTS: Real-time quantitative PCR and RT-PCR products sequencing showed that the number of VHL gene copies in peripheral blood of the patient was decreased, and pathological germline mutation was detected caused by single copy deletion of exon 2 of VHL gene. The patient was diagnosed as atypical VHL RCC according to clinical manifestations and genetic testing outcomes.
CONCLUSIONS: VHL RCC can be diagnosed based on its clinical manifestations and genetic testing results. 2019 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Von Hippel-Lindau Syndrome; diagnosis; genetic testing; germline mutation; von Hippel-Lindauzon gene (VHL gene)

Year:  2019        PMID: 31930078      PMCID: PMC6944587          DOI: 10.21037/atm.2019.10.09

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  13 in total

1.  LINDAU'S DISEASE. REVIEW OF THE LITERATURE AND STUDY OF A LARGE KINDRED.

Authors:  K L MELMON; S W ROSEN
Journal:  Am J Med       Date:  1964-04       Impact factor: 4.965

Review 2.  Role of VHL gene mutation in human cancer.

Authors:  William Y Kim; William G Kaelin
Journal:  J Clin Oncol       Date:  2004-12-15       Impact factor: 44.544

3.  Renal involvement in von Hippel-Lindau disease.

Authors:  D Chauveau; C Duvic; Y Chrétien; F Paraf; D Droz; P Melki; O Hélénon; S Richard; J P Grünfeld
Journal:  Kidney Int       Date:  1996-09       Impact factor: 10.612

4.  Identification of the von Hippel-Lindau disease tumor suppressor gene.

Authors:  F Latif; K Tory; J Gnarra; M Yao; F M Duh; M L Orcutt; T Stackhouse; I Kuzmin; W Modi; L Geil
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

Review 5.  The von Hippel-Lindau tumor suppressor gene and kidney cancer.

Authors:  William G Kaelin
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

Review 6.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

7.  Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.

Authors:  Sreenivasulu Chintala; Tanbir Najrana; Karoly Toth; Shousong Cao; Farukh A Durrani; Roberto Pili; Youcef M Rustum
Journal:  BMC Cancer       Date:  2012-07-17       Impact factor: 4.430

8.  Nothing Iffy about HIF in the Hypothalamus.

Authors:  Sam Virtue; Antonio Vidal-Puig
Journal:  PLoS Biol       Date:  2011-07-26       Impact factor: 8.029

9.  Genotype-phenotype correlations in Chinese von Hippel-Lindau disease patients.

Authors:  Shuanghe Peng; Matthew J Shepard; Jiangyi Wang; Teng Li; Xianghui Ning; Lin Cai; Zhengping Zhuang; Kan Gong
Journal:  Oncotarget       Date:  2017-06-13

Review 10.  Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies.

Authors:  Emily Kim; Stefan Zschiedrich
Journal:  Front Pediatr       Date:  2018-02-09       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.